A detailed history of China Universal Asset Management Co., Ltd. transactions in Verona Pharma PLC stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 20,200 shares of VRNA stock, worth $325,422. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,200
Previous 20,200 -0.0%
Holding current value
$325,422
Previous $325,000 -0.0%
% of portfolio
0.04%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$15.3 - $20.24 $81,426 - $107,717
5,322 Added 35.77%
20,200 $325,000
Q4 2023

May 21, 2024

SELL
$11.94 - $20.47 $63,544 - $108,941
-5,322 Reduced 26.35%
14,878 $295,000
Q4 2023

Jan 23, 2024

SELL
$11.94 - $20.47 $487,223 - $835,298
-40,806 Reduced 73.28%
14,878 $296,000
Q3 2023

May 21, 2024

BUY
$16.3 - $22.09 $567,419 - $768,974
34,811 Added 166.78%
55,684 $907,000
Q3 2023

Oct 30, 2023

BUY
$16.3 - $22.09 $567,419 - $768,974
34,811 Added 166.78%
55,684 $908,000
Q2 2023

May 21, 2024

BUY
$19.41 - $23.43 $388,413 - $468,857
20,011 Added 2321.46%
20,873 $441,000
Q2 2023

Jul 27, 2023

BUY
$19.41 - $23.43 $388,413 - $468,857
20,011 Added 2321.46%
20,873 $441,000
Q1 2023

May 21, 2024

BUY
$18.06 - $25.27 $4,424 - $6,191
245 Added 39.71%
862 $17,000
Q1 2023

Apr 27, 2023

BUY
$18.06 - $25.27 $4,424 - $6,191
245 Added 39.71%
862 $17,000
Q4 2022

May 21, 2024

SELL
$9.84 - $26.13 $192,696 - $511,703
-19,583 Reduced 96.95%
617 $16,000
Q4 2022

Jan 31, 2023

BUY
$9.84 - $26.13 $6,071 - $16,122
617 New
617 $16,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $982M
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.